TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Pejić, Ivana
AU  - Mijić, Smiljana
AU  - Pejčić, Aleksandra
AU  - Đurđević-Svraka, Anita
AU  - Svraka, Dragan
AU  - Knežević, Darija
AU  - Milivojac, Tatjana
AU  - Bogavac-Stanojević, Nataša
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5025
AB  - Background: The pandemic of severe acute respiratory syndrome by coronavirus 2 (SARS-CoV-2) is a multi-system disease caused by a diffuse systemic process involving a complex interaction of the inflammatory, immunological and coagulative cascades. This study aims to identify the most effective biomarkers to predict poor outcome in intensive care unit (ICU) patients with severe COVID-19 disease. Methods: A single-centre retrospective observational study enrolled 69 deceased and 20 recovered patients treated in the ICU of the General Hospital Gradiska in the period from March 1, 2021. until April 1, 2022. We evaluated the leukocytes (WBC), lymphocytes (LYM), neutrophils (NEU), platelets (PLT), haemoglobin, neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In addition, we evaluated the IL-6, ferritin, CRP, D-dimer, magnesium, bilirubin and lactate dehydrogenase. Results: Between deceased and recovered patients on admission to the ICU, there was a significant differencebetween the following parameters: WBC x10 9/L 11.50 (8.86–14.75) vs. 9.40 (5.90–11.90), p =0.026 ; NEU x10 9 /L 10.15 (7.81–12.74) vs. 8.60 (4.80–10.30) p=0.022 ; NLR 15.01 (10.60–24.33) vs. 9.45 (5.10– 14.90) p=0.02 ; SII 3712 (2240–6543) vs. 1949 (993–3720) p=0.003 . The magnesium level increased significantly over time in the patients who died, while the haemoglobin level and platelet count decreased. ROC analysis showed the following AUC values: WBC 0.774; NEU 0.781; NLR 0.786; SII 0.776; D-dimer 0.741, and bilirubin 0.713. Conclusion: In this retrospective study WBC, NEU, NLR, SII, D-dimer, and bilirubin determined at hospital admission had a high value in predicting death among patients with severe COVID-19.
AB  - Uvod: Pandemija teškog akutnog respiratornog sindroma koronavirusa 2 (SARS-CoV-2) je multisistemska bolest izazvana difuznim sistemskim procesom koji uključuje kompleksne interakcije inflamatornih, imunoloških i koagulacionih kaskadnih procesa. Cilj ove studije je da utvrdi najefikasnije biomarkere u proceni lošeg ishoda pacijenata u jedinici intenzivne nege (ICU) obolelih od teškog oblika bolesti COVID-19. Metode: Retrospektivna opservaciona studija je uključivala 69 preminulih i 20 preživelih pacijenata lečenih u ICU u Opštoj bolnici Gradiška u periodu od 01.03.2021. do 01.04.2022. godine. Procenjivane su vrednosti leukocita (WBC), limfocita (LYM), neutrofila (NEU), trombocita (PLT), hemoglobina, odnosa neutrofila i limfocita (NLR), odnosa trom bocita i limfocita (PLR), sistemskog inflama tornog indeksa (SII). Takođe, procenjivane su vrednosti inter leukina6, feritina, CRP, D-dimera, magnezijuma, bilirubina i aktivnost laktat dehidrogenaze. Rezultati: Prilikom prijema pacijenata u ICU postojala je značajna razlika u vrednostima sledećih parametara između preminulih i preživelih pacijenata: WBC x 109/L 11,50 (8,86-14,75) prema (vs.) 9,40 (5,90-11,90), p=0,026; NEU x109/L 10,15 (7,81-12,74) vs. 8,60 (4,80-10,30) p=0,022; NLR 15,01 (10,60-24,33) vs. 9,45 (5,10-14,90) p=0,02; SII 3712 (2240-6543) vs. 1949 (993-3720) p=0,003. Takođe, tokom vremena koncentracija magnezijuma je značajno rasla u grupi preminulih pacijenata, dok je koncentracija hemoglobina i broj trombocita opadao. ROC analiza je pokazala sledeće AUC vrednosti: WBC 0,774; NEU 0,781; NLR 0,786; SII 0,776; D-dimer 0,741 i bilirubin 0,713. Zaključak: U ovoj retrospektivnoj studiji WBC, NEU, NLR, SII, D-dimer i bilirubin, određeni pri prijemu u ICU, su imali visoku vrednost u predviđanju smrti između pacijenata s teškim COVID-19.

PB  - Society of Medical Biochemists of Serbia
T2  - Journal of Medical Biochemistry
T1  - The predictive role of biochemical markers on outcomes of severe Covid-19 patients admitted to intensive care unit
T1  - Uloga biohemijskih markera u predviđanju ishoda teško obolelih Covid-19 pacijenata primljenih na jedinicu intenzivnog lečenja
VL  - 42
IS  - 3
SP  - 513
EP  - 523
DO  - 10.5937/jomb0-40641
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Pejić, Ivana and Mijić, Smiljana and Pejčić, Aleksandra and Đurđević-Svraka, Anita and Svraka, Dragan and Knežević, Darija and Milivojac, Tatjana and Bogavac-Stanojević, Nataša",
year = "2023",
abstract = "Background: The pandemic of severe acute respiratory syndrome by coronavirus 2 (SARS-CoV-2) is a multi-system disease caused by a diffuse systemic process involving a complex interaction of the inflammatory, immunological and coagulative cascades. This study aims to identify the most effective biomarkers to predict poor outcome in intensive care unit (ICU) patients with severe COVID-19 disease. Methods: A single-centre retrospective observational study enrolled 69 deceased and 20 recovered patients treated in the ICU of the General Hospital Gradiska in the period from March 1, 2021. until April 1, 2022. We evaluated the leukocytes (WBC), lymphocytes (LYM), neutrophils (NEU), platelets (PLT), haemoglobin, neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and systemic immune-inflammation index (SII). In addition, we evaluated the IL-6, ferritin, CRP, D-dimer, magnesium, bilirubin and lactate dehydrogenase. Results: Between deceased and recovered patients on admission to the ICU, there was a significant differencebetween the following parameters: WBC x10 9/L 11.50 (8.86–14.75) vs. 9.40 (5.90–11.90), p =0.026 ; NEU x10 9 /L 10.15 (7.81–12.74) vs. 8.60 (4.80–10.30) p=0.022 ; NLR 15.01 (10.60–24.33) vs. 9.45 (5.10– 14.90) p=0.02 ; SII 3712 (2240–6543) vs. 1949 (993–3720) p=0.003 . The magnesium level increased significantly over time in the patients who died, while the haemoglobin level and platelet count decreased. ROC analysis showed the following AUC values: WBC 0.774; NEU 0.781; NLR 0.786; SII 0.776; D-dimer 0.741, and bilirubin 0.713. Conclusion: In this retrospective study WBC, NEU, NLR, SII, D-dimer, and bilirubin determined at hospital admission had a high value in predicting death among patients with severe COVID-19., Uvod: Pandemija teškog akutnog respiratornog sindroma koronavirusa 2 (SARS-CoV-2) je multisistemska bolest izazvana difuznim sistemskim procesom koji uključuje kompleksne interakcije inflamatornih, imunoloških i koagulacionih kaskadnih procesa. Cilj ove studije je da utvrdi najefikasnije biomarkere u proceni lošeg ishoda pacijenata u jedinici intenzivne nege (ICU) obolelih od teškog oblika bolesti COVID-19. Metode: Retrospektivna opservaciona studija je uključivala 69 preminulih i 20 preživelih pacijenata lečenih u ICU u Opštoj bolnici Gradiška u periodu od 01.03.2021. do 01.04.2022. godine. Procenjivane su vrednosti leukocita (WBC), limfocita (LYM), neutrofila (NEU), trombocita (PLT), hemoglobina, odnosa neutrofila i limfocita (NLR), odnosa trom bocita i limfocita (PLR), sistemskog inflama tornog indeksa (SII). Takođe, procenjivane su vrednosti inter leukina6, feritina, CRP, D-dimera, magnezijuma, bilirubina i aktivnost laktat dehidrogenaze. Rezultati: Prilikom prijema pacijenata u ICU postojala je značajna razlika u vrednostima sledećih parametara između preminulih i preživelih pacijenata: WBC x 109/L 11,50 (8,86-14,75) prema (vs.) 9,40 (5,90-11,90), p=0,026; NEU x109/L 10,15 (7,81-12,74) vs. 8,60 (4,80-10,30) p=0,022; NLR 15,01 (10,60-24,33) vs. 9,45 (5,10-14,90) p=0,02; SII 3712 (2240-6543) vs. 1949 (993-3720) p=0,003. Takođe, tokom vremena koncentracija magnezijuma je značajno rasla u grupi preminulih pacijenata, dok je koncentracija hemoglobina i broj trombocita opadao. ROC analiza je pokazala sledeće AUC vrednosti: WBC 0,774; NEU 0,781; NLR 0,786; SII 0,776; D-dimer 0,741 i bilirubin 0,713. Zaključak: U ovoj retrospektivnoj studiji WBC, NEU, NLR, SII, D-dimer i bilirubin, određeni pri prijemu u ICU, su imali visoku vrednost u predviđanju smrti između pacijenata s teškim COVID-19.
",
publisher = "Society of Medical Biochemists of Serbia",
journal = "Journal of Medical Biochemistry",
title = "The predictive role of biochemical markers on outcomes of severe Covid-19 patients admitted to intensive care unit, Uloga biohemijskih markera u predviđanju ishoda teško obolelih Covid-19 pacijenata primljenih na jedinicu intenzivnog lečenja",
volume = "42",
number = "3",
pages = "513-523",
doi = "10.5937/jomb0-40641"
}

Mirjanić-Azarić, B., Pejić, I., Mijić, S., Pejčić, A., Đurđević-Svraka, A., Svraka, D., Knežević, D., Milivojac, T.,& Bogavac-Stanojević, N.. (2023). The predictive role of biochemical markers on outcomes of severe Covid-19 patients admitted to intensive care unit. in Journal of Medical Biochemistry
Society of Medical Biochemists of Serbia., 42(3), 513-523.
https://doi.org/10.5937/jomb0-40641

Mirjanić-Azarić B, Pejić I, Mijić S, Pejčić A, Đurđević-Svraka A, Svraka D, Knežević D, Milivojac T, Bogavac-Stanojević N. The predictive role of biochemical markers on outcomes of severe Covid-19 patients admitted to intensive care unit. in Journal of Medical Biochemistry. 2023;42(3):513-523.
doi:10.5937/jomb0-40641 .

Mirjanić-Azarić, Bosa, Pejić, Ivana, Mijić, Smiljana, Pejčić, Aleksandra, Đurđević-Svraka, Anita, Svraka, Dragan, Knežević, Darija, Milivojac, Tatjana, Bogavac-Stanojević, Nataša, "The predictive role of biochemical markers on outcomes of severe Covid-19 patients admitted to intensive care unit" in Journal of Medical Biochemistry, 42, no. 3 (2023):513-523,
https://doi.org/10.5937/jomb0-40641 . .

TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Jelić-Ivanović, Zorana
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Juergens, Guenther
AU  - Milivojac, Tatjana
AU  - Avram, Sanja
AU  - Ćorić, Jozo
AU  - Marc, Janja
AU  - Černe, Darko
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2432
AB  - Background: High-density lipoproteins (HDL) have atheroprotective biological properties: antioxidative, anti-apoptotic, anti-inflammatory, and they have the efflux capacity of cellular cholesterol. Plasma mRNA analysis can be used to investigate statin pleiotropy in vivo as a new analytical tool for non-invasive assessment of gene expression in vascular beds. The aim of this study was to assess the pleiotropic effects of atorvastatin in stable angina patients with highrisk values (group A) as compared with patients who had borderline and desirable HDL-cholesterol (HDL-C) values (group B). Methods: The atorvastatin therapy (20 mg/day) was given to forty-three patients with stable angina for 10 weeks. We investigated three statin pleiotropy-targeted genes: intercellular adhesion molecule-1, chemokine (C-C motif) ligand 2 and cathepsin S and assessed by gel electrophoresis gradient the effects of atorvastatin on HDL size and subclasses. Results: In group A, after therapy, HDL-C concentration was significantly increased but not in group B. Atorvastatin lowered plasma chemokine (C-C motif) ligand 2 and intercellular adhesion molecule-1 mRNA levels in both groups, but did not change the plasma cathepsin S mRNA levels. In group A only, baseline total bilirubin showed negative cor relations with the genes of cathepsin S (r=-0.506; p = 0.023) and significantly increased after therapy. Conclusions: HDL-C and bilirubin can be promising therapeutic targets in the treatment of cardiovascular diseases. Analysis of cell-free mRNA in plasma might become a useful tool for estimating statin pleiotropy.
AB  - Uvod: Lipoproteini velike gustine (HDL) imaju ateroprotektivne biološke osobine: antioksidativne, antiapoptotičke, antiinflamatorne kao i kapacitet da izvlače holesterol iz ćelija. Analiza plazmatske mRNA može da se koristi za ispitivanje plejotropnih efekata statina in vivo kao novo analitičko sredstvo za neinvazivnu procenu ekspresije gena u zidu krvnog suda. Cilj ove studije je bio da se procene plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom sa visokorizičnim vrednostima (grupa A) u odnosu na pacijente sa graničnim i poželjnim vrednostima HDL holesterola (HDLC) (grupa B). Metode: Četrdeset tri pacijenta sa stabilnom anginom su primala terapiju atorvastatinom (20 mg/dan) 10 nedelja. Mi smo ispitivali tri gena značajna za plejotropno delovanje statina: intracelularni adhezioni molekul-1, hemokin (C-C motiv) ligand 2 i katepsin S i procenjivali smo efekte atorvastatina na veličinu i raspodelu HDL subfrakcija pomoću elektroforeze na poliakrilamidnom gradijent gelu. Rezultati: U grupi A, posle terapije, HDL-C koncentracija se značajno povećala, ali ne i u grupi B. Atorvastatin je snizio plazmatski nivo hemokin (C-C motiv) liganda 2 i intracelularnog adhezionog molekula-1 mRNA u obe grupe, ali nije promenio plazmatski nivo gena za katepsin S. Samo u grupi A, ukupni bilirubin je pokazao negativnu korelaciju sa genom za katepsin S (r = -0,506; p = 0,023) pre započinjanja terapije i značajni porast nakon terapije atorvastatinom. Zaključak: HDL-C i bilirubin mogu biti obećavajući terapijski ciljevi u lečenju kardiovaskularnih bolesti. Analiza slobodne mRNA (eng. cell-free mRNA) u plazmi može postati korisno sredstvo za procenu plejotropnog delovanja statina.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA
T1  - Plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom - dokazi dobijeni analizom veličine i raspodele subfrakcija lipoproteina velike gustine i plazmatske mRNA
VL  - 34
IS  - 3
SP  - 314
EP  - 322
DO  - 10.2478/jomb-2014-0058
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Jelić-Ivanović, Zorana and Zeljković, Aleksandra and Vekić, Jelena and Juergens, Guenther and Milivojac, Tatjana and Avram, Sanja and Ćorić, Jozo and Marc, Janja and Černe, Darko",
year = "2015",
abstract = "Background: High-density lipoproteins (HDL) have atheroprotective biological properties: antioxidative, anti-apoptotic, anti-inflammatory, and they have the efflux capacity of cellular cholesterol. Plasma mRNA analysis can be used to investigate statin pleiotropy in vivo as a new analytical tool for non-invasive assessment of gene expression in vascular beds. The aim of this study was to assess the pleiotropic effects of atorvastatin in stable angina patients with highrisk values (group A) as compared with patients who had borderline and desirable HDL-cholesterol (HDL-C) values (group B). Methods: The atorvastatin therapy (20 mg/day) was given to forty-three patients with stable angina for 10 weeks. We investigated three statin pleiotropy-targeted genes: intercellular adhesion molecule-1, chemokine (C-C motif) ligand 2 and cathepsin S and assessed by gel electrophoresis gradient the effects of atorvastatin on HDL size and subclasses. Results: In group A, after therapy, HDL-C concentration was significantly increased but not in group B. Atorvastatin lowered plasma chemokine (C-C motif) ligand 2 and intercellular adhesion molecule-1 mRNA levels in both groups, but did not change the plasma cathepsin S mRNA levels. In group A only, baseline total bilirubin showed negative cor relations with the genes of cathepsin S (r=-0.506; p = 0.023) and significantly increased after therapy. Conclusions: HDL-C and bilirubin can be promising therapeutic targets in the treatment of cardiovascular diseases. Analysis of cell-free mRNA in plasma might become a useful tool for estimating statin pleiotropy., Uvod: Lipoproteini velike gustine (HDL) imaju ateroprotektivne biološke osobine: antioksidativne, antiapoptotičke, antiinflamatorne kao i kapacitet da izvlače holesterol iz ćelija. Analiza plazmatske mRNA može da se koristi za ispitivanje plejotropnih efekata statina in vivo kao novo analitičko sredstvo za neinvazivnu procenu ekspresije gena u zidu krvnog suda. Cilj ove studije je bio da se procene plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom sa visokorizičnim vrednostima (grupa A) u odnosu na pacijente sa graničnim i poželjnim vrednostima HDL holesterola (HDLC) (grupa B). Metode: Četrdeset tri pacijenta sa stabilnom anginom su primala terapiju atorvastatinom (20 mg/dan) 10 nedelja. Mi smo ispitivali tri gena značajna za plejotropno delovanje statina: intracelularni adhezioni molekul-1, hemokin (C-C motiv) ligand 2 i katepsin S i procenjivali smo efekte atorvastatina na veličinu i raspodelu HDL subfrakcija pomoću elektroforeze na poliakrilamidnom gradijent gelu. Rezultati: U grupi A, posle terapije, HDL-C koncentracija se značajno povećala, ali ne i u grupi B. Atorvastatin je snizio plazmatski nivo hemokin (C-C motiv) liganda 2 i intracelularnog adhezionog molekula-1 mRNA u obe grupe, ali nije promenio plazmatski nivo gena za katepsin S. Samo u grupi A, ukupni bilirubin je pokazao negativnu korelaciju sa genom za katepsin S (r = -0,506; p = 0,023) pre započinjanja terapije i značajni porast nakon terapije atorvastatinom. Zaključak: HDL-C i bilirubin mogu biti obećavajući terapijski ciljevi u lečenju kardiovaskularnih bolesti. Analiza slobodne mRNA (eng. cell-free mRNA) u plazmi može postati korisno sredstvo za procenu plejotropnog delovanja statina.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA, Plejotropni efekti atorvastatina kod pacijenata sa stabilnom anginom - dokazi dobijeni analizom veličine i raspodele subfrakcija lipoproteina velike gustine i plazmatske mRNA",
volume = "34",
number = "3",
pages = "314-322",
doi = "10.2478/jomb-2014-0058"
}

Mirjanić-Azarić, B., Jelić-Ivanović, Z., Zeljković, A., Vekić, J., Juergens, G., Milivojac, T., Avram, S., Ćorić, J., Marc, J.,& Černe, D.. (2015). The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 34(3), 314-322.
https://doi.org/10.2478/jomb-2014-0058

Mirjanić-Azarić B, Jelić-Ivanović Z, Zeljković A, Vekić J, Juergens G, Milivojac T, Avram S, Ćorić J, Marc J, Černe D. The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA. in Journal of Medical Biochemistry. 2015;34(3):314-322.
doi:10.2478/jomb-2014-0058 .

Mirjanić-Azarić, Bosa, Jelić-Ivanović, Zorana, Zeljković, Aleksandra, Vekić, Jelena, Juergens, Guenther, Milivojac, Tatjana, Avram, Sanja, Ćorić, Jozo, Marc, Janja, Černe, Darko, "The Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA" in Journal of Medical Biochemistry, 34, no. 3 (2015):314-322,
https://doi.org/10.2478/jomb-2014-0058 . .

TY  - JOUR
AU  - Mirjanić-Azarić, Bosa
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Đerić, Mirjana
AU  - Milivojac, Tatjana
AU  - Fonović, Ursa Pecar
AU  - Marc, Janja
AU  - Kos, Janko
AU  - Cerne, Darko
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2069
AB  - Aim: We hypothesized that, in stable angina patients, atorvastatin therapy lowers the cathepsin S (CTSS) concentrations, as assessed non-invasively according to a plasma analysis. In addition, the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) size and subclasses in the plasma were analysed to establish the association between CTSS and lipoprotein metabolism and determine whether this association is atorvastatin-sensitive. Methods: A total of 43 patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). The plasma CTSS mRNA levels, CTSS protein concentrations and CTSS activity, as well as LDL and HDL size and subclasses, were analysed before and after treatment. Results: Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. An increased plasma CTSS concentration and activity were found to be associated with a more atherogenic LDL subclass profile (a decreased dominant LDL size and increased percentage of small, dense LDL particles). The atorvastatin-induced CTSS-lowering effect was concomitant with an improvement in the LDL subclass profile, and the changes were found to be interrelated. Concomitant, interrelated changes in the CTSS levels and LDL subclass profiles were found in the LDL phenotype B patients only (a dominant LDL diameter of  lt = 25.5 nm at the start of the study). In this subgroup, lowering of the plasma CTSS mRNA level also correlated with lowering of the proportion of small, dense LDL particles. Conclusions: Atorvastatin-induced CTSS-lowering and LDL subclass profile improvements in the plasma of LDL phenotype B patients with stable angina are concomitant and interrelated.
PB  - Japan Atherosclerosis Soc, Tokyo
T2  - Journal of Atherosclerosis and Thrombosis
T1  - Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients
VL  - 21
IS  - 8
SP  - 868
EP  - 877
DO  - 10.5551/jat.21410
ER  - 

@article{
author = "Mirjanić-Azarić, Bosa and Vekić, Jelena and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Đerić, Mirjana and Milivojac, Tatjana and Fonović, Ursa Pecar and Marc, Janja and Kos, Janko and Cerne, Darko",
year = "2014",
abstract = "Aim: We hypothesized that, in stable angina patients, atorvastatin therapy lowers the cathepsin S (CTSS) concentrations, as assessed non-invasively according to a plasma analysis. In addition, the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) size and subclasses in the plasma were analysed to establish the association between CTSS and lipoprotein metabolism and determine whether this association is atorvastatin-sensitive. Methods: A total of 43 patients with stable angina received atorvastatin therapy (20 mg/day, 10 weeks). The plasma CTSS mRNA levels, CTSS protein concentrations and CTSS activity, as well as LDL and HDL size and subclasses, were analysed before and after treatment. Results: Atorvastatin treatment did not change the plasma CTSS mRNA levels, although it lowered the plasma CTSS concentrations and activity. An increased plasma CTSS concentration and activity were found to be associated with a more atherogenic LDL subclass profile (a decreased dominant LDL size and increased percentage of small, dense LDL particles). The atorvastatin-induced CTSS-lowering effect was concomitant with an improvement in the LDL subclass profile, and the changes were found to be interrelated. Concomitant, interrelated changes in the CTSS levels and LDL subclass profiles were found in the LDL phenotype B patients only (a dominant LDL diameter of  lt = 25.5 nm at the start of the study). In this subgroup, lowering of the plasma CTSS mRNA level also correlated with lowering of the proportion of small, dense LDL particles. Conclusions: Atorvastatin-induced CTSS-lowering and LDL subclass profile improvements in the plasma of LDL phenotype B patients with stable angina are concomitant and interrelated.",
publisher = "Japan Atherosclerosis Soc, Tokyo",
journal = "Journal of Atherosclerosis and Thrombosis",
title = "Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients",
volume = "21",
number = "8",
pages = "868-877",
doi = "10.5551/jat.21410"
}

Mirjanić-Azarić, B., Vekić, J., Zeljković, A., Jelić-Ivanović, Z., Đerić, M., Milivojac, T., Fonović, U. P., Marc, J., Kos, J.,& Cerne, D.. (2014). Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients. in Journal of Atherosclerosis and Thrombosis
Japan Atherosclerosis Soc, Tokyo., 21(8), 868-877.
https://doi.org/10.5551/jat.21410

Mirjanić-Azarić B, Vekić J, Zeljković A, Jelić-Ivanović Z, Đerić M, Milivojac T, Fonović UP, Marc J, Kos J, Cerne D. Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients. in Journal of Atherosclerosis and Thrombosis. 2014;21(8):868-877.
doi:10.5551/jat.21410 .

Mirjanić-Azarić, Bosa, Vekić, Jelena, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Đerić, Mirjana, Milivojac, Tatjana, Fonović, Ursa Pecar, Marc, Janja, Kos, Janko, Cerne, Darko, "Interrelated Cathepsin S-Lowering and LDL Subclass Profile Improvements Induced by Atorvastatin in the Plasma of Stable Angina Patients" in Journal of Atherosclerosis and Thrombosis, 21, no. 8 (2014):868-877,
https://doi.org/10.5551/jat.21410 . .